TrialDiabetologia2016

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.